Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for March 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during March 2014.

For an indepth analysis of these deals, read 'Pharma deals during March 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Vidara Therapeutics/
Horizon Pharma
Merger/ acquisition
Actimmune (interferon gamma-1b) for CGD and SMO (approved)
660
Five Prime Therapeutics/ BMS
Collaboration, licence
Drug discovery against two undisclosed targets in immune checkpoint pathways

350.5
AnaptysBio/ Tesaro
Collaboration, licence
mAbs to activate immune system response "checkpoints" - 3 targets: TIM-3, LAG-3 and PD-1 (preclinical)

341
Revive Pharmaceuticals/ Concordia Healthcare
Product acquisition
Donnatal, adjunctive therapy for IBS and acute enterocolitis (marketed)

265.3
*Takeda Pharmaceutical/ Otsuka Pharmaceutical
Co-promotion
TAK-438 (vonoprazan fumarate) for acid-related diseases (NDA filed JP)

195+
Galapagos/ Charles River
Acquisition of CRO business
Drug discovery services business

185
Activaero/  Vectura
Acquisition (cash + equity)
Portfolio of nebuliser-based respiratory products and technologies

181
Caisson Biotech/ Novo Nordisk
Licence
HEPtune drug delivery technology for half-life extension - insulin and other therapeutics (preclinical)
167
UCB/ Sanofi
Collaboration - discovery/ development
Anti-inflammatory small molecules for treatment of immune-mediated disorders (discovery)

138.5
TxCell/ Ferring
Collaboration, option,  licence
Ovasave - personalised cell-based immunotherapy for IBD (inc Crohn's disease, ulcerative colitis) (p2)

105
Sumitomo Chemical/ AstraZeneca
Acquisition of remaining shares
AZ takes complete control of AstraZeneca KK

102
**Bayer/ Kythera Biopharmaceuticals
Buy back of rights ex US, Canada (Aug 2010 deal)
ATX-101 - submental contouring injectable drug (p3)

84
Sarasvati Venture Capital/ GSK
Acquisition of remaining 30% shares
GSK takes full control of its Indonesian consumer health unit
26.6
‡SK Chemicals/ Sanofi Pasteur
Collaboration
Pneumococcal conjugate vaccine (PCV) 23
Genmab/ Janssen
Milestone payment
Daratumumab, anti-CD38 mAb for multiple myeloma (p2 milestone)
22
Tracon Pharmaceuticals/ Santen Pharmaceutical Co
Licence
Tracon's anti‐endoglin antibodies, including TRC105 for wet AMD (p2)
10
‡‡BioAlliance Pharma/ Innocutis
Licence
Sitavig® (acyclovir Lauriad®) for recurrent herpes labialis (approved)
5


All deals are worldwide unless otherwise noted – see below:
    
*       Japan     
**     Outside US, Canada
‡         Sanofi Pasteur has rights outside Korea; SK has exclusive rights for Korea
‡‡      North America

CGD = chronic granulomatous disease
SMO = severe, malignant osteopetrosis

 

The Deal Watch table is compiled by Medius Associates

11th April 2014

The Deal Watch table is compiled by Medius Associates

11th April 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Infographics